[1]
|
Panaccio M, Zalcberg JR, Thompson CH, et al. Heteroge-neity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo[J]. Immunol Cell Biol, 1987, 65:461-472. doi: 10.1038/icb.1987.55 |
[2]
|
Burnet FM. The concept of immunological surveillance[J]. Prog Exp Tumor Res, 1970, 13:1-27. doi: 10.1159/000386035 |
[3]
|
Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E[J]. J Exp Med, 1992, 176:1453-1457. doi: 10.1084/jem.176.5.1453 |
[4]
|
Jensen PE. Recent advances in antigen processing and presentation[J]. Nat Immunol, 2007, 8:1041-1048. doi: 10.1038/ni1516 |
[5]
|
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J]. Curr Opin Immunol, 2012, 24:207-212. doi: 10.1016/j.coi.2011.12.009 |
[6]
|
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11: 3887-3895. doi: 10.1002/j.1460-2075.1992.tb05481.x |
[7]
|
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331 |
[8]
|
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5:1365-1369. doi: 10.1038/70932 |
[9]
|
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2:261-268. doi: 10.1038/85330 |
[10]
|
Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition[J]. Am J Clin Oncol, 2016, 39:98-106. doi: 10.1097/COC.0000000000000239 |
[11]
|
Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal[J]. Nat Immunol, 2009, 10:1185-1192. doi: 10.1038/ni.1790 |
[12]
|
Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance[J]. J Exp Med, 2006, 203:883-895. doi: 10.1084/jem.20051776 |
[13]
|
Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation[J]. J Immunol, 2004, 173:945-954. doi: 10.4049/jimmunol.173.2.945 |
[14]
|
Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mech-anisms[J]. Mol Cell Biol, 2005, 25:9543-9553. doi: 10.1128/MCB.25.21.9543-9553.2005 |
[15]
|
Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers[J]. Br J Cancer, 2015, 112:1421-1427. doi: 10.1038/bjc.2015.124 |
[16]
|
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase Ⅱ trial[J]. J Clin Oncol, 2015, 33:1430-1437. doi: 10.1200/JCO.2014.59.0703 |
[17]
|
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366:2443-2454. doi: 10.1056/NEJMoa1200690 |
[18]
|
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373:1803-1813. doi: 10.1056/NEJMoa1510665 |
[19]
|
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial[J]. Lancet, 2016, 387:1909-1920. doi: 10.1016/S0140-6736(16)00561-4 |
[20]
|
Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2016, 100:88-98. doi: 10.1016/j.critrevonc.2016.02.001 |
[21]
|
McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates from a Phase Ia Study[J]. J Clin Oncol, 2016, 34:833-842. doi: 10.1200/JCO.2015.63.7421 |
[22]
|
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372:320-330. doi: 10.1056/NEJMoa1412082 |
[23]
|
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373:123-135. doi: 10.1056/NEJMoa1504627 |
[24]
|
Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study[J]. J Clin Oncol, 2017, 35:3851-3858. doi: 10.1200/JCO.2016.72.1985 |
[25]
|
Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma[J]. Ther Adv Urol, 2015, 7:365-377. doi: 10.1177/1756287215597647 |
[26]
|
Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer[J]. P T, 2011, 36:197-202. |
[27]
|
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine[J]. Clin Caner Res, 2011, 17:3520-3526. doi: 10.1158/1078-0432.CCR-10-3126 |
[28]
|
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase Ⅲ trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer[J]. J Clin Oncol, 2006, 24:3089-3094. doi: 10.1200/JCO.2005.04.5252 |
[29]
|
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl Med, 2010, 363:411-422. doi: 10.1056/NEJMoa1001294 |
[30]
|
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86: 10024-10028. doi: 10.1073/pnas.86.24.10024 |
[31]
|
Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365:725-733. doi: 10.1056/NEJMoa1103849 |
[32]
|
Cheadle EJ, Gornall H, Baldan V, et al. CAR-T cells: Driving the road from the laboratory to the clinic[J]. Immunol Rev, 2014, 257:91-106. doi: 10.1111/imr.12126 |
[33]
|
Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering[J]. Nature, 2017, 545:423-431. doi: 10.1038/nature22395 |
[34]
|
Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2[J]. Cancer, 1997, 80:1198-1220. doi: 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H |